Athira Sethu
Kochi, 11 Dec 2025
Cipla has launched obesity drug in Indian market. Here is a snapshot of its Q2FY26 performance as pharma stocks see renewed interest from investors.
Financial Performance Q2FY26:
| Metric | Q2 FY26 | Rise/FalYoY |
| Revenue (₹ Cr) | 7,589.44 | 8% ↑ |
| Net Profit (₹ Cr) | 1,353.37 | 4% ↑ |
| EBITDA Margin | 25% | 1.78%↓ |
| PAT Margin | 17.8% | NA |
| EPS (₹) | 16.73 | 16.07 |
Half-Yearly Performance
| Metric | H1 FY26 (₹ Cr) | Rise/Fall YoY |
| Total Income | 15,074.42 | 6.94% ↑ |
| Net Profit | 2,644.98 | 6.63% ↑ |
Revenue Breakup:
| Metric | % of Revenue |
| One India | 41% |
| North America | 27% |
| One Africa | 16% |
| Emerging Markets & Europe | 13% |
| API | 2% |
(Source: Exchange Filings & Investor Presentation)
